Cinda Perryman
Family · Fayette, MSNPI 1841699758
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,889 of the $3,447 with a category attached, or 83.8%. 5 manufacturers reported payments, led by Eli Lilly at 54.4% of the total. Reporting peaked in 2023 at $3,412 and has fallen 99.4% since, to $20 in 2025.
Across 18 payments — averaging $191.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2K
- Boehringer Ingelheim International GmbH$2K
- Amgen$36
- Merck$17
- Lilly USA, LLC$15
Across 20 payments — averaging $45,083 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$900K
- Regeneron$2K
What the payments were for
- Travel & lodging$2,88984%
- Food & beverage$55816%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 3 | $1,875 |
| Boehringer Ingelheim International GmbH | 11 | $1,505 |
| Amgen | 2 | $36 |
| Merck | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
How this compares
$3,447 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 107 | $121,463 |
| JanuviaSitagliptin Phosphate | 90 | $88,964 |
| OzempicSemaglutide | 46 | $51,890 |
| LinzessLinaclotide | 64 | $39,745 |
| JardianceEmpagliflozin | 32 | $35,483 |
| JanumetSitagliptin Phos/Metformin Hcl | 26 | $23,753 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $21,543 |
| FarxigaDapagliflozin Propanediol | 19 | $18,218 |
| EliquisApixaban | 23 | $14,933 |
| TradjentaLinagliptin | 14 | $11,093 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 117 | $3,156 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,436 |
| Megestrol Acetate | 19 | $2,215 |
| Atorvastatin Calcium | 378 | $2,179 |
| Potassium Chloride | 196 | $1,938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $15 | $121,463107 claims |
| MerckJanuvia, Janumet | $17 | $112,718116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.
Other family in Fayette
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
- Andrea WallaceOlive Branch$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.